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Increased vaccine hesitancy and refusal negatively affects vaccine uptake leading to vaccine 
preventable disease reemergence. We aimed to quantify the relative importance of 
characteristics people consider when making vaccine decisions for themselves, or for their 
child, with specific attention for underlying motives arising from context, such as required 
effort (accessibility) and opportunism (free riding on herd immunity).  
 
Methods 
We documented attitudes towards vaccination and performed a discrete choice experiment in 
4802 respondents in The United Kingdom, France and Belgium eliciting preferences for six 
attributes: (1) vaccine effectiveness, (2) vaccine preventable disease burden, (3) vaccine 
accessibility in terms of co-payment, vaccinator and administrative requirements, (4) frequency 
of mild vaccine-related side-effects, (5) vaccination coverage in the country’s population and 
(6) local vaccination coverage in personal networks. We distinguished adults deciding on 
vaccination for themselves (‘oneself’ group) from parents deciding for their youngest child 
(‘child’ group).  
 
Results 
While all six attributes were found to be significant, vaccine effectiveness and accessibility 
stand out in all (sub)samples, followed by vaccine preventable disease burden. We confirmed 
that people attach more value to severity of disease compared to its frequency and discovered 
that peer influence dominates free-rider motives, especially for the vaccination of children.  
 
Conclusions 
These behavioral data are insightful for policy and are essential to parameterize dynamic 
vaccination behavior in simulation models. In contrast to what most game theoretical models 
assume, social norms dominate free-rider incentives. Therefore policy-makers and healthcare 
workers should actively communicate on high vaccination coverage, and draw attention to the 
effectiveness of vaccines, while optimizing their practical accessibility. 
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Background  
Vaccination remains a cornerstone of global public health, preventing about 2 to 3 million 
deaths each year [1]. However, its success is currently undermined by growing vaccine 
hesitancy and refusal. Sentiments underpinning this have multi-faceted origins, not least 
distorted perceptions of severe vaccine side-effects, much of which can be traced back to 
fraudulent research linking measles-mumps-rubella (MMR) vaccination with autism [2, 3], and 
misconceptions about the use of adjuvants in vaccines [4]. Others include doubts about vaccine 
effectiveness [3, 5] and about our immune system’s coping with the rising number of 
recommended vaccine antigens [3, 6]. More extreme attitudes are based on government and 
vaccine industry conspiracy theories [3], religious beliefs (e.g. Protestantism in the Dutch Bible 
Belt [7]) and “back to nature” motives (i.e. preferring immunity acquired by natural infection 
to vaccine-induced immunity, under the belief that “divine or natural” risks are smaller and/or 
more “just” than those imposed by human interventions) [3].  
Even though vaccine controversies are not new [8, 9], the internet and a variety of social media 
have amplified the spread of misinformation and allowed the establishment of new online anti-
vaccine communities [10]. According to a 2018 Gallup poll [11], only 40% and 59% of Eastern 
and Western Europeans, respectively, believe vaccines are safe. In Northern Europe and 
Northern America, these figures are higher at 73% and 72%, respectively [11].  
As a result of these misperceptions, plunging vaccination rates and immunity levels have been 
observed in recent years. Notably so for measles, which is a highly virulent pathogen for which 
a safe and effective vaccine was already approved by the Food and Drug Administration (FDA) 
in 1971 [12]. Indeed, the European Centre for Disease Prevention and Control (ECDC) recently 
reported the existence of a large pool of people in the EU that are susceptible to measles due 
to low historical and current vaccination coverage. Only 4 countries achieved two dose measles 
vaccination coverage of at least 95% in 2017, compared to 14 countries in 2007. 
Unsurprisingly, measles resurgence has recently been observed, with 44,074 cases in 30 EU 
member states between 2016 and March 2019 [13]. The same trend has been observed in the 
US, with 704 cases reported in the first four months of 2019 (even though the US declared 
elimination of endemic transmission in 2000) [14, 15].  
Mathematical and economic models have proven valuable to simulate and evaluate the impact 
of prevention measures on the spread, burden and economics of infectious diseases. These 
models inform and guide policy-makers to prepare for and respond to (re)emerging infectious 
diseases, particularly when sufficient information from controlled experiments is lacking. 
However, because of the reasons previously touched upon, the impact of prevention measures 
and other policy interventions are subject to hosts’ compliance and demand. In response, 
behavioral change models have been developed to incorporate dynamic behavior (i.e. the 
demand side of prevention measures) into models for infectious disease transmission. As a 
result of circulating controversies and -usually positive- externalities, vaccination models have 
become particularly interesting to take dynamic behavior into account. Indeed, vaccination 
usually results in positive externalities, often referred to as ‘herd immunity’: successfully 
vaccinated individuals do not (or hardly) transmit the pathogen to others. As such the marginal 
utility of vaccination decreases (non-linearly) as coverage increases, and endemic transmission 
can often be halted without vaccinating the whole population, a phenomenon which is crucial 
for vulnerable individuals who cannot receive vaccination due to age or medical reasons (e.g. 
too young or immuno-compromised). Where positive externalities exist, game theory applies. 
Hence, models have been developed in which rational-behaving individuals are assumed to 
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free-ride on ‘herd immunity’, and therefore increasingly refuse vaccination when they perceive 
more members of the population to be immunized. However, the majority of behavioral change 
models in the published literature remains purely theoretical, lacking parameterization with 
empirical data and a validation process [16, 17]. Consequently, data for parameterization of 
behavioral change models are highly desirable to construct improved models mimicking 
realistic vaccination behavior. This is generally recognized as one of the challenges for 
behavioural change models [18].  
Discrete choice experiments (DCEs) have proven successful to elicit preferences and quantify 
the decision- making process with respect to vaccine characteristics in multiple studies [19–
26]. Moreover, they are well established as an instrument in health economic research in 
general [27]. A DCE is a quantitative surveying technique in which respondents make a choice 
between two or more hypothetical profiles in consecutive choice sets. Profiles are represented 
by attributes with (partially) differing attribute levels [28]. In previous DCEs, vaccines were 
described using attributes such as vaccine effectiveness [19, 20, 22–25, 29], vaccine-related 
side-effects (VRSE) [19–24, 29] or in terms of vaccine price (whether or not including costs 
of vaccine administration) [19, 21–24, 26]. A recent study found that DCEs correctly predicted 
influenza vaccination choices on an aggregate level when taking scale and preference 
heterogeneities into account [30].  
In this paper, we report on the findings of a DCE quantifying individual preferences for 
vaccination attributes in Belgium, the United Kingdom (UK) and France. We present these 
new results together with those of two separately reported DCEs using an identical design, 
conducted in South Africa and The Netherlands [24, 31]. We aim to: 1) generate and 
communicate behavioral data with respect to vaccines in order to move from theory to data-
driven behavioral change models in infectious disease epidemiology, 2) assess to what extent 
individual vaccination decisions are driven by social norms or peer pressure as opposed to free-
riding motives, 3) identify the vaccine characteristics society values most, and 4) accommodate 
policy-makers and health care professionals to select focal points in their communication to 
hesitant individuals.  
Methods  
We conducted a survey in France, the UK (both early December 2018) and Belgium (May 
2019). We selected these countries for a number of reasons. First of all, no DCE had yet been 
performed for a general, unnamed vaccine, distinguishing between adults and children in any 
of these countries. Also, we were interested in between-country differences comparing 
different backgrounds, cultures and more specifically, a different history with respect to 
vaccination. France was included in this study because it has been experiencing a lot of vaccine 
resistance: one in three French inhabitants now believes vaccines are unsafe, which is the 
highest fraction in the world [11]. More specifically, there is a lot of vaccine resistance in 
France originating from safety concerns regarding the pandemic A/H1N1 flu vaccine with 
spillovers to other vaccines (e.g. MMR vaccine) [11, 32]. As a result, the French government 
expanded the number of compulsory vaccines from 3 to 11 in 2018 [11]. The UK was included 
because it has a history of vaccine scares with documented impact on vaccine coverage for the 
whole cell pertussis vaccine in the 1970s and 1980s [33] and MMR vaccine in the 2000s [2]. 
We also included Belgium, a country with a more neutral vaccination history, achieving 
generally high and stable vaccine coverage in young children [34]. However, regional 
disparities have been observed to widen [35], and one in five Belgian citizens believe vaccines 
are unsafe [11]. In order to facilitate broader between-country comparisons, we report our 
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results alongside those of two more studies using an identical design in South Africa and The 
Netherlands, conducted in December 2017 and June-July 2018, respectively, and published in 
detail elsewhere [24, 31].  
Given that the design of the questionnaire was explicitly developed for cross-country 
comparisons, the majority of the survey questions and the entire DCE design were kept the 
same as in South Africa and The Netherlands, which in turn were based on a study in Flanders 
in 2017 [23]. The survey questionnaire is provided as a supplement to the paper by Hoogink et 
al. [31] and as a supplement to this paper (additional file 2). We adapted the survey questions 
to reflect country-specific characteristics based on inputs from local experts, for example with 
respect to the educational system and the organization of the national immunization schedule. 
As such, we ended up with four versions of the survey for the UK, France, French speaking 
Belgium, and Dutch speaking Belgium. The multi-country study protocol as well as the 
amendments to the original questionnaires (Reference number: 15/2/12) were reviewed and 
accepted by the Ethical Committee of the Antwerp University Hospital (UZA, Belgium). Given 
that this study was non-interventional, and carried out in a general population (adults only) 
with informed consent, duplicate ethical approval at a local committee was not deemed 
necessary by our IRB, and we therefore did not re-apply for it with a local committee. We 
tested each survey version in a soft launch in which we asked about 10% of the target sample 
to fill out the survey and evaluate the comprehensibility of the questions. Afterwards, we 
launched the survey in the sample population. The survey consisted of five sections: 1) 
background questions probing for age, gender, marital status, occupation, smoking behavior, 
etc., 2) 21 attitudinal questions on vaccines where responses were recorded on a five-point 
Likert scale, ranging from completely agree to completely disagree, 3) a DCE with 10 choice 
sets based on Verelst et al. [23], including an introduction text with instructions and a sample 
choice set to familiarize the respondents with the DCE, 4) four questions probing for relative 
risk perceptions based on a survey by Bults et al. [36], and 5) a health literacy test with three 
questions from Chew et al. [37]. Based on their background characteristics, we allocated 
respondents to two distinct surveys: a ‘oneself’ group (without allocation restrictions) and a 
‘youngest child’ group (only for respondents having at least one child below the age of 18 
years), the former filling out the survey with respect to vaccination decisions for themselves, 
the latter doing so for their youngest child. We opted for a sample size of about 1500 
respondents per country, based on previous DCEs with the same design [23, 24, 31]. We 
gradually built each sample to better match the sample demographics to the population 
demographics, and thus to obtain a more representative sample. We recruited respondents from 
an online consumer panel applying an efficient participant allocation algorithm. In total, 9339 
respondents started the survey, 4802 of them completed the survey, 1213 chose not to complete 
it, 59 did not meet the inclusion criteria (e.g., <18 years old), 119 were identified as ‘speeders’ 
(who filled out the survey much faster than a reference time) and/or ‘straight-liners’ (who filled 
out the same for each question), and 3146 were halted after the first part of the survey with 
background questions when pre-defined sample quota were reached. We incentivized 
participation through credit rewards, transferable into coupons and gift vouchers. Only one 
member per household could participate in the study. Country and group level sample 
characteristics are displayed in Table 1.  
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Table 1. Sample characteristics and national statistics for Belgium, France & The UK.  
*age groups from the survey are compared to age groups [15-29], [30-49], [50-64] and [65-
84] as reported in the 2011 census database [40]. 
Characteristic Belgium United Kingdom France 
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Age group (*) 
  18-34  
  35-49  
  50-65  































Educational attainment      
  Primary education (ISCED 
1) or lower  
  Secondary education 
(ISCED 2+3)  
  Post-secondary or (post- 
)university education 
(ISCED 4 or higher)  























































NUTS 1 region 
  Belgium 
  Flanders 
  Walloon region 
  Brussels Capital Region 
  UK 
  North East 
  North West 
  Yorkshire and the Humber      
  East Midlands 
  West Midlands 
  East of England 
  London 
  South East 
  South West 
  Wales 
  Scotland 
  Northern Ireland  
  France 
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The DCE was characterized by a Bayesian D-efficient design [28] of 50 choice sets with 2 
profiles described by 6 attributes with 3 varying and 3 constant levels and optimized for the 
precise estimation of all main effects as well as all two-way interactions between any of the six 
attributes and ‘vaccine effectiveness’, ‘VRSE’ and ‘accessibility’. We divided the design into 
five surveys of 10 choice sets that we distributed evenly between all participants. We selected 
the attributes and attribute levels through a literature study, a focus group study and a pilot 
study in Flanders, the details of which are published in Verelst et al. [23]. We revised the 
description of VRSE by specifying the severity of side-effects, keeping severe side-effects to 
be ‘highly unlikely’ in the two profiles, and only varying the frequency of mild VRSE. This 
contrasts with the original design in Verelst et al. [23], where we left the severity of side-effects 
unspecified, but is the same as in Verelst et al. [24] and Hoogink et al. [31]. We opted for this 
strategy since it prevents the participant from imagining levels regarding VRSE severity and it 
mimics real-life VRSE, because vaccines with common severe side-effects should not be 
licensed. We included population and local coverage as attributes to assess the magnitude of 
free-riding behavior in the populations under study. Negative utility values for higher coverage 
levels confirm free-riding behavior, as opposed to positive utility values, in which case peer 
influence and social norms dominate. All attributes and attribute levels are shown in Table 2.  
Table 2. DCE attributes and levels. 
 
We analysed the DCE using the JMP Pro 14 Choice Platform [38] and applied a Panel Mixed 
Logit (PML) modeling approach with 10,000 Bayesian iterations, with the last 5,000 used for 
estimation. We distinguished between models estimating the attribute effects - allowing for 
model comparison between study populations - and models including interaction effects 
between the attributes and respondent covariates - allowing for identifiable preference 
heterogeneity within study populations. In the latter, we systematically estimated covariate 
interactions one-by-one, keeping record of all the statistically significant model terms including 
the main effects. Afterwards, we estimated a joint model combining all main effects and 
individually significant interactions. We dropped insignificant interactions in an iterative 
Attribute  Level description 
1. Vaccine effectiveness a) Protects 50% of vaccinated persons 
b) Protects 90% of vaccinated persons 
2. Burden of disease a) The disease, against which the vaccine protects is rare and often mild: 
hospitalisation is exceptional and the disease is not life-threatening 
b) The disease, against which the vaccine protects is rare and often severe: often 
with hospitalisation and the disease is life-threatening 
c) The disease, against which the vaccine protects is common and often mild: 
hospitalisation is exceptional and the disease is not life-threatening  
d) The disease, against which the vaccine protects is common and often severe: 
often with hospitalisation and the disease is life-threatening 
3. VRSE a) Mild side-effects commonly occur and severe side-effects are highly unlikely 
b) Mild side-effects rarely occur and severe side-effects are highly unlikely  
4. Accessibility  a) The vaccine is provided for free and is directly available at the vaccinator 
(GP, well-baby clinic, school- or occupational physician) 
b) The vaccine is not reimbursed and is only available with a prescription 
5. Local coverage  a) 30% of your acquaintances (friends and family) is vaccinated 
b) 60% of your acquaintances (friends and family) is vaccinated 
c) 90% of your acquaintances (friends and family) is vaccinated 
6. Population coverage  a) 30% of the population in general is vaccinated 
b) 60% of the population in general is vaccinated 
c) 90% of the population in general is vaccinated  
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process until we reached a model with the most important covariates. We ranked the significant 
model terms by importance using the normalized LogWorth statistic, i.e. -log10(p-value of the 
LR-test), where the LR-test is short for the likelihood ratio test for significance of a given 
model term. We used RStudio [39] for cleaning the raw survey data and creating the bar charts.  
Results  
We managed to retrieve a quasi-representative sample of about 1600 survey respondents in 
each country, as shown in Table 1. Women are slightly overrepresented in the samples from 
the UK and France. We found a representative population with respect to age to be 
incompatible with having at least 750 respondents with children below the age of 18. Moreover, 
concerning educational attainment, the samples are also somewhat biased towards the higher 
educated, especially so in France. This is likely because older French respondents, who tend to 
be lower educated, are underrepresented in our sample. Note however, that the youngest age 
groups are by definition lower educated since the census data also include school-age teenagers 
(15-18 years). We investigated the impact of mismatching sample characteristics by estimating 
covariate interactions between the attributes and gender, educational attainment and region, 
and found none of them to significantly influence our findings. Significant covariate 
interactions with respondents’ age group are included and reported in Appendix A.  
Vaccine attitudes tended to be positive in general as represented in Figures 1 and 2 for a 
selection of general vaccine statements. We observed French respondents in the ‘adult’ group 
to be relatively neutral towards the statements “The people who are important to me think that 
I must get vaccinated” and “I have confidence in the information about vaccinations that I 
receive from the Government”. These sentiments appeared to be more negative in the ‘adult’ 
group than for the ‘child group’. In contrast, the respondents from the UK were in general more 
agreeing on this selection of statements. The median UK respondent strongly agreed with the 
statements “I think that getting vaccinated against infectious diseases is wise” and “I think that 
getting vaccinated against infectious diseases is important” in the ‘adult’ group, whereas in the 
‘child’ group the median UK respondent strongly agreed with the statements “The diseases that 
are vaccinated against can be very serious” and “I think that vaccinating my child according to 
the National Vaccination Program is important”. Other ‘child’ group samples, on average, 
agree on all statements, though there is a lot of variability within the samples. Attitudes from 
Belgian and Dutch respondents were usually found in between the UK and the French sample 
means. Details on all 21 attitudinal questions are presented in Appendix B.  
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Figure 2. Likert scale responses for a selection of vaccination attitude statements in the 
‘child’ group. 
 
All six attributes were found to be statistically significant in all five countries. The normalized 
LogWorth values represent the relative importance of the attributes in each country and 
subgroup, and are visualized in Figure 3. Two attributes stand out: vaccine effectiveness and 
accessibility. Vaccine effectiveness is the key characteristic for all survey respondents in the 
UK and South Africa, but also for the ‘child’ group in The Netherlands. For the Belgian 
population as well as the French ‘oneself’ group, accessibility was found to be most important. 
The French ‘child’ group attached most importance to burden of disease, whereas this was 
considered much less important by the same subpopulation in the UK. We found local coverage 
and mild VRSE to be also statistically significant but of limited importance in most study 
samples, with a relative importance of 30% or less. Population coverage was found to have 
more influence, especially so in the case of ‘child’ models, with the Netherlands being an 
exception. Note that among all five countries mild VRSE had the highest impact in vaccine 
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Figure 3. Importance of all statistically significant (p-value <0.05) main effects relative to 
the most important attribute in each study sample. 
 
For both population and local coverage, estimates were found to be positive for all subsamples 
in all study countries (see Tables 3 to 5). Hence, respondents were more inclined to choose a 
vaccine if it already had a high coverage in their network of contacts and in the population at 
large. For example, for the ‘child’ group in France, a 10% increase in the population’s 
vaccination coverage increases vaccine utility by 0.108 on average (see Table 5).  
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Table 3. Panel mixed logit model estimates (means and standard deviations) and 
significances of the attribute effects obtained from likelihood ratio (LR) tests. Belgium 
Term Mean estimate (std dev; 






  Co-payment & prescription 
  Free & accessible 
 
-0.403 (0.020; 0.334)  








  50% 
  90% 
 
-0.465 (0.024; 0.244)  







Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.436 (0.045; 0.615)  
-0.481 (0.047; 0.361)  
 0.324 (0.037; 0.128)  










Population coverage (x10%)  0.081 (0.008; 0.099) 65.749 1 <0.0001 
Mild VRSE 
  Common 
  Rare 
 
-0.184 (0.019; 0.098)  







Local coverage (x10%)  0.043 (0.008; 0.079) 17.977 1 <0.0001 
‘Youngest child’ model 
Accessibility 
  Co-payment & prescription 
  Free & accessible 
 
-0.472 (0.031; 0.346)  








  50% 
  90% 
 
-0.571 (0.037; 0.245)  







Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.370 (0.058; 0.463)  
-0.613 (0.062; 0.418)  
 0.307 (0.056; 0.284)  










Population coverage (x10%)  0.128 (0.012; 0.126) 93.449 1 <0.0001 
Mild VRSE 
  Common 
  Rare 
 
-0.234 (0.028; 0.137)  
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Table 4. Panel mixed logit model estimates (means and standard deviations) and 
significances of the attribute effects obtained from likelihood ratio (LR) tests. United 
Kingdom 
Term Mean estimate (std dev; 






  50% 
  90% 
 
-0.683 (0.035; 0.275)  








  Co-payment & prescription 
  Free & accessible 
 
-0.486 (0.023; 0.316)  







Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.517 (0.049; 0.277)  
-0.351 (0.051; 0.430)  
 0.307 (0.045; 0.206)  










Population coverage (x10%)  0.096 (0.010; 0.118) 94.330 1 <0.0001 
Mild VRSE 
  Common 
  Rare 
 
-0.180 (0.024; 0.124)  







Local coverage (x10%)  0.080 (0.010; 0.078) 47.291 1 <0.0001 
‘Youngest child’ model 
Vaccine effectiveness 
  50% 
  90% 
 
-0.591 (0.033; 0.243)  








  Co-payment & prescription 
  Free & accessible 
 
-0.309 (0.024; 0.233)  







Population coverage (x10%)  0.107 (0.009; 0.101) 94.979 1 <0.0001 
Local coverage (x10%)  0.097 (0.010; 0.094) 67.461 1 <0.0001 
Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.198 (0.055; 0.266)  
-0.344 (0.042; 0.305)  
 0.187 (0.045; 0.178)  











  Common 
  Rare 
 
-0.143 (0.026; 0.087)  
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Table 5. Panel mixed logit model estimates (means and standard deviations) and 
significances of the attribute effects obtained from likelihood ratio (LR) tests. France 
Term Mean estimate (std dev; 






  Co-payment & prescription 
  Free & accessible 
 
-0.389 (0.026; 0.410)  








  50% 
  90% 
 
-0.375 (0.030; 0.222)  







Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.364 (0.052; 0.318)  
-0.358 (0.042; 0.416)  
 0.273 (0.048; 0.224)  










Population coverage (x10%)  0.079 (0.010; 0.131) 48.157 1 <0.0001 
Mild VRSE 
  Common 
  Rare 
 
-0.164 (0.027; 0.092)  







Local coverage (x10%)  0.064 (0.010; 0.093) 33.480 1 <0.0001 
‘Youngest child’ model 
Burden of disease 
  Rare & mild  
  Common & mild  
  Rare & severe  
  Common & severe  
 
-0.369 (0.048; 0.300)  
-0.474 (0.051; 0.323)  
 0.331 (0.049; 0.202)  











  50% 
  90% 
 
-0.430 (0.029; 0.231)  








  Co-payment & prescription 
  Free & accessible 
 
-0.314 (0.023; 0.278)  







Population coverage (x10%)  0.108 (0.010; 0.135) 88.489 1 <0.0001 
Mild VRSE 
  Common 
  Rare 
 
-0.180 (0.026; 0.098)  







Local coverage (x10%)  0.078 (0.010; 0.086) 44.981 1 <0.0001 
Note: Mean estimates corresponding to the last level of an attribute are calculated as minus the sum 
of the estimates for the other levels of the attribute.  
 
 
Vaccine effectiveness stands out as the most important attribute in the UK, South Africa and 
in the ‘child’ group in the Netherlands. In Belgium and France, we found vaccine effectiveness 
to be a crucial element as well, at a relative importance of about 80% and 60% respectively. In 
all countries, vaccine effectiveness was ranked more important, or equally important, in the 
‘child’ group compared to the ‘oneself’ group.  
In contrast, vaccine accessibility was valued higher, or equally,  in the ‘oneself’ group 
compared to the ‘child’ group in all countries, except for South Africa. In addition, accessibility 
was the most important attribute in Belgium, and in the ‘oneself’ group in France and the 
Netherlands.  
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The ‘child’ group in France cared most about the burden of the disease. This attribute was also 
of considerable importance in the same group in the Netherlands. There are notable differences 
in valuation of this attribute between all subgroups involved. Indeed, in the UK sample, the 
burden of disease was valued at a relative importance of about 40% in the ‘oneself’ group and 
about 20% in the ‘child’ group. Whereas in the Netherlands, France and Belgium, this attribute 
was valued at a relative importance of about 50% or more.  
We observed a clear distinction between the ‘oneself’ group and the ‘child’ group with respect 
to population coverage. Indeed, both these indicators of vaccination coverage were considered 
relatively more important for children than for adults in all countries except the Netherlands. 
This implies that when parents decide about vaccinating their child, they are more prone to 
peer influence, than when adults (including parents) make these decisions for themselves. 
Overall, both population and local coverage were considered most important in France and 
South Africa and least important in the Netherlands and the UK.  
Mild VRSE and local coverage were, although statistically significant for all subgroups, found 
to be of the relative lowest importance in most countries and subgroups.  
Attribute-level utility estimates are listed in Tables 3 to 5. As could be expected, respondents 
in all study populations preferred the most a vaccine with 90% effectiveness, that is free & 
accessible, protects against a common & severe disease, rarely exhibits mild VRSE and for 
which vaccination coverage is high. In addition, we consistently found disease severity to 
dominate frequency of disease in all study samples.  
The models including the attributes’ main effects as well as the most important covariate 
interactions are provided in Appendix A. Vaccine-related attitude statements were able to 
explain most preference heterogeneity. For example for Belgium, in the ‘oneself’ model we 
discovered respondents agreeing (disagreeing) with the statement “The available vaccinations 
are suited to protect my health” attached more (less) value to a vaccine with an efficacy of 90% 
(50%), compared to the average (see Figure S1 below). Moreover, we also found that in the 
‘oneself’ model for the UK, respondents indicating that they were at low risk of contracting 
measles, cared more about the vaccine being free & accessible (see Figure S3 above). The same 
is true for individuals agreeing with “vaccinating my child is the logical thing to do” in the 
‘child’ model for the UK (see Figure S4 above). For details on additional covariate interactions, 
we refer to Appendix A.  
Discussion  
The need for behavioral data in relation to infectious disease epidemiology and prevention has 
been raised repeatedly over the past decade [16–18]. Our multi-country series of DCEs 
generated highly valuable data for parameterization and validation of epidemiological models. 
This is because data-driven hosts’ behavior derived from DCEs can be added to models 
mimicking the spread of infectious diseases. For example, dynamic behavior can be modelled 
through a utility function using prevalence utility estimates from the burden of disease attribute. 
As such, the utility of a vaccine increases when a disease becomes more prevalent. Similar 
dynamics can be modelled using the utility estimates of population or local coverage. 
Moreover, exogenous shocks, such as changing risk perceptions, can be introduced in such 
integrated models. Utility estimates on vaccine effectiveness, accessibility, disease severity and 
mild VRSE can facilitate data-driven introductions of exogenous shocks. Furthermore, the 
multi-country character of our study allows modelling vaccination behavior in five countries. 
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However, an integrated model combining data-driven vaccination behavior with infectious 
disease transmission dynamics, requires the specification of a dichotomous vaccine outcome 
(to be vaccinated or not) based on individual utilities derived from vaccine attributes. That is, 
a function that derives vaccine uptake from utility associated with vaccination. Future research 
will explore the specification of such vaccine uptake functions.  
The positive estimates for both coverage attributes in all (sub)samples imply social norms or 
peer influence are more important than free-rider incentives. These findings confirm the 
positive coverage estimates reported in vaccination DCEs in Australia [19] and in the US [26]. 
Overall, it seems unlikely that respondents take externalities - such as herd immunity - into 
account when making vaccine decisions. As such, game theoretical models characterizing 
vaccine decisions as a strategic interaction between rational individuals, seem inappropriate to 
capture real-life vaccination dynamics. If individuals do include herd immunity effects in their 
decisions, it might very well be the case that they behave altruistically and opt for vaccination, 
contributing to the protection of vulnerable individuals. This was observed in several empirical 
studies, such as the study by Skea et al. [41] reporting on ‘avoiding harm to others’ incentives 
in the context of MMR vaccination in the UK. They found parents on a chat forum to be critical 
towards parents not vaccinating their healthy children, thereby putting vulnerable ones at risk. 
Altruistic motives were also described in the papers by Hakim et al. [42] and Shim et al. [43] 
in the context of influenza vaccination, and by Vietri et al. [44] about assessing the extent of 
altruism with respect to human papillomavirus (HPV) and influenza vaccination. Policy-
makers and healthcare workers can influence vaccine hesitant individuals by communicating 
high coverage levels, i.e. describing that “accepting the vaccine is the mainstream thing to do”, 
in addition to other strategies (see Leask et al. [45] for a framework on “communicating with 
parents about vaccination”).  
Vaccine accessibility has proven highly significant in our study, as well as in other studies [19, 
22, 24–26], where it was, however, mostly described in terms of out-of-pocket or total costs. 
For example, Wong et al. [46] performed a DCE on mothers’ preferences for HPV vaccination 
in Hong Kong and found a significant impact of out-of-pocket cost on the decision to receive 
the vaccine. Poulos et al. [47] reported similar results with respect to traveler vaccines. This 
has also been confirmed by observational studies. For instance, in a retrospective cohort study, 
Lefevere et al. [48] found both personal information letters and removing out-of-pocket costs 
had a significant positive effect on HPV vaccination initiation in Belgium.  
Given the importance of vaccine accessibility, policy-makers can increase vaccine coverage 
by making vaccines easily available at an affordable price. There is still significant room for 
improvement concerning adults (cfr. the ‘oneself group’) who are often confronted with an 
expensive, complicated and time consuming process of vaccination. Take for instance 
influenza vaccination in Belgium, where individuals typically visit a General Practitioner (GP) 
for a prescription, then buy the vaccine (often without reimbursement) at a pharmacy and lastly 
have to go back to the GP to be vaccinated. Not surprisingly, influenza vaccine coverage has 
usually been below 25% [49]. Adults cannot rely on the routine vaccination services available 
for children (e.g. well-baby clinics, child health clinics or school health centres). In this respect, 
(expansion of) workplace vaccination can play a vital role in facilitating vaccination for 
working-age adults. Policy-makers should consider incentivizing employers to offer certain 
vaccines to their employees at the workplace, e.g. influenza, and tetanus, diphtheria and 
pertussis (Tdap) vaccination, or hepatitis A for employees working in the food industry. 
Workplace vaccination may also prove useful in catch-up campaigns which would, for 
example, be required to maintain measles elimination targets [50–52]. Note that for the ‘child’ 
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group, accessibility was found to be very important as well. Policy-makers should remain 
focused on making vaccines as accessible as possible for both groups.  
In line with previous studies [22, 24, 46], vaccine effectiveness was observed to be of great 
importance in all models. Therefore it is essential that the public should remain fully aware of 
the positive impact vaccines are having on population health. According to a 2018 Gallup poll, 
the effectiveness of vaccines is perceived to be significantly more reliable than their safety. Of 
the five countries included in our study, France scored worst with about 20% of the population 
disagreeing that vaccines are effective, followed by The Netherlands and South Africa both at 
11% [11].  
In a previous study in Flanders [23], we applied the same DCE design but did not specify the 
severity of VRSE. The updated description in this study, varying only mild VRSE and 
describing severe VRSE as being ‘highly unlikely’, shifted the attribute’s importance from the 
highest rank in the earlier study, to one of the lowest ranks in the current. Safety concerns with 
respect to vaccinations remain crucial in vaccine misperceptions. VRSE may indeed occur, but 
are mostly mild and clear up quickly [53]. In this study it became clear that when respondents 
used realistic information on vaccine side-effects they cared less about them while making 
vaccination decisions. Acknowledging the existence of VRSE and providing risk and benefit 
information is recommended when discussing safety concerns with potential vaccine recipients 
(or their parents) [45]. The relative importance of burden of disease is more volatile and appears 
to be country-specific. In the ‘child’ model for the UK, we found it to be relatively unimportant, 
whereas for the same subpopulation in France, burden of disease was most important. The 
severity of the infectious disease was found to be more important than the frequency of the 
disease. This is in line with Sadique et al. [21], who showed severity of both vaccine-
preventable disease and VRSE to be more important than their frequency. To address concerns 
about the burden of disease and VRSE, healthcare workers as key informants, should be well-
versed in the general topic of vaccination and should use standard guidelines for each vaccine 
and disease so that potential vaccine recipients are consistently and well-informed. See also 
Leask et al. [45], who provide a vaccine communication framework.  
Conclusions  
In conclusion, we found slightly different preferences for vaccine attributes between countries. 
Nonetheless, there are communalities in that people’s vaccine decisions seem to depend in the 
first place on how they perceive the effectiveness and risks of severe VRSE, as well as the 
burden of vaccine preventable disease. Their decisions are also influenced significantly by how 
easy it is to be vaccinated, in terms of effort and costs, by the possibility of mild VRSE and by 
how many other people are being vaccinated. Especially vaccination of the population in 
general is an important element when having a child vaccinated. Therefore communication 
strategies on vaccination should not forget to include information on vaccination rates, 
reflecting that vaccination is still the norm, and non-vaccination remains exceptional. Contrary 
to what most game theoretical models assume, this information would be an incentive to 
receive vaccination, rather than to forego it intending to take a free ride.  
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